Please click on the 'Read full article' link below for an update on the current situation with Di-gesic and Doloxene.Read More
Aspen Australia (Aspen) wishes to advise that it is unexpectedly out of stock of Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg).Read More
Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the ninth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the year ended 30 June 2013.Read More
The Australian competition authorities have approved Aspen's acquisition of the Australian IN business and the transaction will be effective in Australia from 28 April 2013.Read More
On 5th April, 2013 the Administrative Appeals Tribunal (AAT) decided that both Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg) and Doloxene (dextropropoxyphene napsylate) should remain on the Australian Register of Therapeutic Goods (ARTG), subject to the implementation of conditions to promote the safe use of these medicines.Read More
Di-Gesic and Doloxene continue to be registered on the Australian Register of Therapeutic Goods (ARTG) and doctors may continue to prescribe both products after carefully considering the indications, warnings and contraindications in the Product Information and Consumer Medicines Information for these products.Read More
Aspen will continue to appeal the Therapeutic Goods Administrationâ€Ÿs decision to de-register Di-Gesic and Doloxene.
The TGA has affirmed its decision to cancel the registration of DPP products, however its decision will not take effect until further order of the AAT. Aspen remains concerned to ensure that patients are not left without adequate pain relief, and considers that this is likely to be the case if Di-Gesic and Doloxene are de-registered. Consequently, Aspen will continue its appeal.
Di-Gesic and Doloxene will remain on the register while Aspenâ€Ÿs appeal is heard and doctors may continue to prescribe both products after carefully considering the indications, warnings and contraindications in the Product Information and Consumer Medicines Information for these products.Read More
Aspen has reached agreement with GSK to acquire a portfolio of 25 products from GSK for the Australian market, subject to ACCC and Foreign Investment Review Board approval.Read More
Recognising the needs of a small group of patients who would be left without adequate pain relief if DiGesic and Doloxene were no longer available, the Administrative Appeals Tribunal (AAT) has declined to uphold a decision of the Minister/TGA to cancel the registrations of DiGesic and Doloxene.Read More
Aspen has acquired a range of OTC products from GSK in a multi-territory transaction.
For Australia, the basket of products has sales of around $17 million, with about $750K in New Zealand. Other Asia-Pacific countries coming under the Aspen Australia umbrella represent sales of around $13.5 million.
The products in Australia are Cartia, Zantac, Lipeze, Quellada and Beconase, all well known power brands which will cement the position of Aspen Australia as one of the leading OTC companies in the country.Read More